CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma.
Eleven patients with advanced progressive metastatic adrenal cortical carcinoma, for whom no further standard therapy was available, were entered into a phase II study of cyclophosphamide, doxorubicin, and cisplatin (CAP) combination chemotherapy. Two partial responses and six disease stabilizations were observed. Patients with partial responses survived 18+ and 23 months; the median survival of patients with disease stabilization was 10+ months. The total group had a median survival of 10+ months. These results, together with the modest toxicity, suggest that further study of the combination is warranted.
D000293:Adolescent; D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D002945:Cisplatin / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin